H1B Report
Side-by-side comparison

AMNEAL PHARMACEUTICALS LLC vs INFOSYS LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
AMNEAL PHARMACEUTICALS LLC
NJRank #FEIN 90-0186021
Entity B
INFOSYS LIMITED
TXRank #1FEIN 58-1760235

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricAMNEAL PHARMACEUTICALS LLCINFOSYS LIMITED
Total filings453205,263
Certified %94.04%99.55%
Denied %0.66%0.21%
Withdrawn %2.65%0.20%
Cert-withdrawn %2.65%0.05%
Rank#1
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateNJTX

Outcomes — AMNEAL PHARMACEUTICALS LLC

DOL case-status mix.

Outcome breakdown: Certified 94.0%, Cert-withdrawn 2.6%, Withdrawn 2.6%, Denied 0.7%
Outcome breakdown
OutcomeShare
Certified94.0%
Cert-withdrawn2.6%
Withdrawn2.6%
Denied0.7%
Certified94.0%
Cert-withdrawn2.6%
Withdrawn2.6%
Denied0.7%

Outcomes — INFOSYS LIMITED

DOL case-status mix.

Outcome breakdown: Certified 99.5%, Cert-withdrawn 0.0%, Withdrawn 0.2%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

AMNEAL PHARMACEUTICALS LLC
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201013
FY201125
FY201225
FY201324
FY201439
FY201551
FY201638
FY201740
FY201838
FY201945
FY20202
FY20216
FY20223
FY202314
FY202434
FY202525
FY202631
INFOSYS LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,164
FY20111,681
FY201214,701
FY201332,232
FY201423,749
FY201533,214
FY201625,335
FY201720,571
FY201811,569
FY201921,420
FY202016
FY202129
FY202222
FY20232,269
FY20245,943
FY20255,790
FY20264,558

Top 5 occupations — AMNEAL PHARMACEUTICALS LLC

Top 5 occupations — INFOSYS LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.